 CAMBRIDGE, Mass., Oct. 11, 2021 GLOBE NEWSWIRE -- Sarepta Therapeutics, Inc. NASDAQ:SRPT, the leader in precision genetic medicine for rare diseases, today shared new analyses and functional data from its SRP-9001 rAAVrh74.MHCK7.micro-dystrophin development program and details of Study SRP-9001-301, known as EMBARK, its global pivotal Phase 3 trial of SRP-9001 for the treatment of Duchenne muscular dystrophy. SRP-9001, being developed in partnership with Roche, is an investigational gene transfer therapy intended to deliver its micro-dystrophin-encoding gene to muscle tissue for the targeted production of the micro-dystrophin protein. 